Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
Article 2019 en
Authors
NS
Nikolaos Spinthakis
YG
Ying X. Gue
MF
Mohamed Farag
Abstract
1 min read
Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.
Iris Lin, Ruslan Horblyuk, Jack Mardekian, Sang Hee Park, Shital Kamble, Melissa Hamilton, Younos Abdulsattar, William Petkun, Joseph Menzin, Professor Gregory Lip
Xiaoyan Li, Steve Deitelzweig, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.